Reviva Pharmaceuticals (RVPH) Proxy filing summary

Executive summary

• Virtual annual meeting scheduled for Dec. 18, 2026; record date Oct. 30, 2026, with five proposals for stockholder action.

• The Board recommends FOR all five proposals: director nominees, auditor ratification, say-on-pay, reverse split authorization and conditional adjournment.

Voting matters and shareholder proposals

• Proposal 1 seeks re-election of five current directors; plurality voting applies, and withholds and broker non-votes do not affect the result.

• Proposal 2 ratifies Baker Tilly for FY2026; Proposal 3 is an annual, non-binding say-on-pay vote, with a majority of votes cast required for each.

• Proposal 4 asks approval for a 1:2 to 1:100 reverse split before Dec. 31, 2027, with the Board deciding whether to implement and selecting the ratio; approval requires a majority of outstanding eligible shares.

• Proposal 5 would permit adjournment, if needed, to solicit more proxies; 2027 bylaw notice window is Aug. 20–Sept. 20, 2027, with Rule 14a-19 notice due Oct. 19, 2027.

Board of directors and corporate governance

• Five directors stand for election; four—Saxena, Funtleyder, Patel and Margolin—were determined independent under Nasdaq and SEC standards.

• The Board met 13 times in 2025; each director attended at least 75% of applicable Board and committee meetings.

• Audit, Compensation, and Governance committees met five, four and one times, respectively, in 2025; Funtleyder chairs Audit and is its financial expert.

• Chair and CEO roles are separated; the full Board oversees risk through committee-chair and responsible-officer reports.